Anavex Life Sciences Corp (AVXL)

[jav0033]

RETT EXCELLENCE failed RSBQ primary and CGI secondary endpoints.

“Clinical Global Impression – Improvement scale (CGI-I), which represents a less granular assessment by the site investigators using a seven-point scoring (one=“very much improved” to seven=“very much worse”), WAS NOT MET”


RSBQ after 12 weeks of treatment, ANAVEX®2-73-treated patients improved LS Mean (SE) -12.93 (2.150) points on their RSBQ total score compared to LS Mean (SE) -8.32 (2.537) points in placebo-treated patients. The LS Mean difference (SE) of -4.61 (2.439) points between treated and placebo groups DID NOT REACH statistical significance (n=77; p=0.063).

https://www.anavex.com/post/anavex-life-sciences-provides-update-rett-syndrome-program?mc_cid=f36acac293